Galapagos, a Belgium biotechnology company recently presented novel corrector / potentiator combination drug candidates for restoring CFTR function at the NACFC. Pre-clinical data was shown in which these novel corrector molecules in combination with existing CFTR modulators restored at least 40% of healthy CFTR in cells from CF patients with the most common mutation, delF508.
These novel corrector molecules, both in combination with potentiator GLPG1837, and with GLPG1837 and a prototype corrector C18, restore >40% of healthy function in cells from patients with the most common mutation, delF508. Galapagos is among the first to pass this hurdle pre-clinically. Galapagos plans to enter Phase 1 with potentiator GLPG1837 and select a pre-clinical candidate corrector before end 2014.
Earlier this year, Galapagos presented preclinical data on five different Galapagos corrector series that in combination with potentiator GLPG1837 restore up to 60% of healthy function in delF508 patient cells.
Galapagos aims to develop combinations of corrector and potentiator medicines to address the needs of the largest CF patient group harboring the delF508 mutation.
2014 NACFC Poster: http://t.co/ffGot3fUS7
- Chris
These novel corrector molecules, both in combination with potentiator GLPG1837, and with GLPG1837 and a prototype corrector C18, restore >40% of healthy function in cells from patients with the most common mutation, delF508. Galapagos is among the first to pass this hurdle pre-clinically. Galapagos plans to enter Phase 1 with potentiator GLPG1837 and select a pre-clinical candidate corrector before end 2014.
Earlier this year, Galapagos presented preclinical data on five different Galapagos corrector series that in combination with potentiator GLPG1837 restore up to 60% of healthy function in delF508 patient cells.
Galapagos aims to develop combinations of corrector and potentiator medicines to address the needs of the largest CF patient group harboring the delF508 mutation.
2014 NACFC Poster: http://t.co/ffGot3fUS7
- Chris